Fremonta Meyer1,2,3, Kalen Fletcher4, Holly G Prigerson5, Ilana M Braun1,2,3, Paul K Maciejewski5. 1. Department of Psychiatry, Brigham and Women's Hospital, Boston, MA, USA. 2. Harvard Medical School, Boston, MA, USA. 3. Department of Psychosocial Oncology and Palliative Care, Dana-Farber Cancer Institute, Boston, MA, USA. 4. Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. 5. Center for Research on End of Life Care, Departments of Medicine and Radiology, Weill Cornell Medical College, New York, NY, USA.
Abstract
OBJECTIVE: Major depression adversely affects health communication, quality of life, and survival in patients with advanced cancer. Prior research provides limited insight into how patients with advanced cancer differ from the general population in risk for developing a major depressive episode (MDE). This study aims to determine whether advanced cancer poses distinct risks for initial and recurrent MDEs. METHODS: Advanced cancer patients (N = 628) from Coping with Cancer were compared with propensity-weighted general population controls (N = 9282) from the National Comorbidity Survey Replication. RESULTS: Patients with advanced cancer were more likely than comparisons to have an initial MDE [OR = 27.3, 95% CI = (14.8-50.4); p < 0.001] but no more likely than comparisons to have a recurrent MDE [OR = 1.5, 95% CI = (0.9-2.6); p = 0.160]. Nearly two thirds (64.4%) of current MDEs in patients were initial onset; the vast majority (91.8%) of current MDEs in comparisons were recurrent. CONCLUSIONS: Advanced cancer increases risk of an initial MDE but appears not to enhance risk of a recurrent MDE. This suggests the importance of screening widely for depression in patients with advanced cancer as opposed to targeting screening to presumably high-risk subgroups of those with psychiatric histories.
OBJECTIVE: Major depression adversely affects health communication, quality of life, and survival in patients with advanced cancer. Prior research provides limited insight into how patients with advanced cancer differ from the general population in risk for developing a major depressive episode (MDE). This study aims to determine whether advanced cancer poses distinct risks for initial and recurrent MDEs. METHODS:Advanced cancerpatients (N = 628) from Coping with Cancer were compared with propensity-weighted general population controls (N = 9282) from the National Comorbidity Survey Replication. RESULTS:Patients with advanced cancer were more likely than comparisons to have an initial MDE [OR = 27.3, 95% CI = (14.8-50.4); p < 0.001] but no more likely than comparisons to have a recurrent MDE [OR = 1.5, 95% CI = (0.9-2.6); p = 0.160]. Nearly two thirds (64.4%) of current MDEs in patients were initial onset; the vast majority (91.8%) of current MDEs in comparisons were recurrent. CONCLUSIONS:Advanced cancer increases risk of an initial MDE but appears not to enhance risk of a recurrent MDE. This suggests the importance of screening widely for depression in patients with advanced cancer as opposed to targeting screening to presumably high-risk subgroups of those with psychiatric histories.
Authors: William F Pirl; Joseph A Greer; Lara Traeger; Vicki Jackson; Inga T Lennes; Emily R Gallagher; Pedro Perez-Cruz; Rebecca S Heist; Jennifer S Temel Journal: J Clin Oncol Date: 2012-03-19 Impact factor: 44.544
Authors: J E Epping-Jordan; B E Compas; D M Osowiecki; G Oppedisano; C Gerhardt; K Primo; D N Krag Journal: Health Psychol Date: 1999-07 Impact factor: 4.267
Authors: Josep Maria Haro; Saena Arbabzadeh-Bouchez; Traolach S Brugha; Giovanni de Girolamo; Margaret E Guyer; Robert Jin; Jean Pierre Lepine; Fausto Mazzi; Blanca Reneses; Gemma Vilagut; Nancy A Sampson; Ronald C Kessler Journal: Int J Methods Psychiatr Res Date: 2006 Impact factor: 4.035
Authors: Martin Härter; Harald Baumeister; Katrin Reuter; Frank Jacobi; Michael Höfler; Jürgen Bengel; Hans-Ulrich Wittchen Journal: Psychother Psychosom Date: 2007 Impact factor: 17.659
Authors: Wendy G Lichtenthal; Matthew Nilsson; Baohui Zhang; Elizabeth D Trice; David W Kissane; William Breitbart; Holly G Prigerson Journal: Psychooncology Date: 2009-01 Impact factor: 3.894
Authors: Lorenzo Cohen; Steven W Cole; Anil K Sood; Sarah Prinsloo; Clemens Kirschbaum; Jesusa M G Arevalo; Nicholas B Jennings; Shellie Scott; Luis Vence; Qi Wei; Diane Kentor; Laszlo Radvanyi; Nizar Tannir; Eric Jonasch; Pheroze Tamboli; Louis Pisters Journal: PLoS One Date: 2012-08-01 Impact factor: 3.240